Apimeds Pharmaceuticals US (APUS) Convertible Debt (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) posted Convertible Debt of $235439.0 for Q3 2025, up 55.68% on a QoQ basis from $151237.0 in Q2 2025.

Apimeds Pharmaceuticals US (APUS) Convertible Debt (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US's Convertible Debt history runs 2 years deep, the most recent figure standing at $235439.0 for Q3 2025.

Quarterly Convertible Debt changed N/A year-over-year to $235439.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $235439.0 (changed N/A YoY) and the FY2024 annual result came in at $346844.0, changed N/A from the prior year.
Convertible Debt was $235439.0 for Q3 2025 at Apimeds Pharmaceuticals US, up from $151237.0 in the prior quarter.
Across five years, Convertible Debt topped out at $346844.0 in Q4 2024 and bottomed at $151237.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Apimeds Pharmaceuticals US	8.17 Mn	8.17 Mn	-

Download Data